Welcome to a thought-provoking episode of our podcast series, where we dive into the ethical and practical challenges of CAR T-cell therapy with Professor Marie José Kersten from Amsterdam University Medical Centers.

In this episode, our host Dr Isabel Olivera engages in a deep dive with Professor Kersten on the intricacies of patient access to CAR T-cell therapy, the ethical considerations in patient selection, and the financial implications of this groundbreaking treatment.

Discover the rigorous process of patient eligibility assessment in the Netherlands, the national CAR-T tumorboard's role, and the ongoing efforts to make CAR T-cell therapy more accessible across different regions. Join us as we explore the potential of clinical trials in advancing treatment options, the quest for cost-effective manufacturing methods, and the critical importance of ethical decision-making in healthcare.

This conversation also offers valuable advice for hematologists and sheds light on the importance of multidisciplinary discussions in improving patient outcomes. Don't miss this insightful discussion that navigates the complexities of modern medicine and the future of lymphoma treatment.

Host: Dr Isabel Olivera Martinez

Guest: Prof Marie José Kersten

This is part of a series recorded at the joint EHA-EBMT 6th European CAR T-cell meeting in Valencia in February 2024, more podcasts will be available in the future. Stay tuned!

Interested in more content related to CART? We've got you covered. Check out free CART program on EHA Campus.

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: education@ehaweb.org

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe

Join us for a conversation with Jonathan Clark, a patient advocate who has been in remission for over five years after receiving CAR T-cell therapy for Mantle Cell Lymphoma.

Jonathan shares his journey from relapse to recovery, detailing the challenges and triumphs of this cutting-edge treatment from a patient’s perspective. With host Dr. Sarah de Vlieger, they discuss his motivation for sharing his story and the profound physical and psychological impacts of long-term remission.

Jonathan also talks about managing long-term side effects like immunodeficiencies and how apparently small changes can significantly improve quality of life. He emphasizes the importance of understanding the patient's perspective, advocating for quality of life improvements, and the need for personalized care that goes beyond medical statistics. Jonathan highlights the global disparities in accessing advanced treatments like CAR T-cell therapy and concludes with a call to prioritize quality of life in treatment decisions.

Host: Dr Sarah de Vlieger

Guest: Jonathan Clark

This episode is part of a series recorded at the joint EHA-EBMT 6th European CAR T-cell meeting in Valencia in February 2024.

Interested in more content related to CART? We've got you covered. Check out free CART program on EHA Campus.

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: education@ehaweb.org

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe

Join us for a captivating interview with our guest Professor Michael Hudecek from the Universitätsklinikum Würzburg in Germany as he offers his insights on the latest advancements in CAR T-cell therapy and gene-engineered immune cell therapies.

Together with our host Dr. Isabel Olivera Martinez, they discuss the mounting real-world data on CAR T-cell treatments and how AI is helping analyze this data to design new strategies and extend CAR-T to new indications.

Discover the strides being made to predict and manage treatment-related toxicities and to make CAR T-cell therapy more accessible and affordable, including potential off-the-shelf treatments and automated manufacturing techniques.

Learn about the role of gene editing and the challenges of creating universally compatible immune cell products. Finally, gain insights from the 2024 CAR T-cell meeting, where groundbreaking clinical updates and new applications of CAR-T to autoimmune and cardiovascular diseases were showcased.

Host: Dr Isabel Olivera Martinez

Guest: Prof Michael Hudecek

This is part of a series recorded at the joint EHA-EBMT 6th European CAR T-cell meeting in Valencia in February 2024, more podcasts will be available in the future. Stay tuned!

Interested in more content related to CART? We've got you covered. Check out free CART program on EHA Campus.

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: education@ehaweb.org

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe